Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 274 of 5804
-
MRNA vaccine aims to prevent shingles in older adults
⭐️ VACCINE ⭐️ Not yet recruitingThe study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of 3 dose levels of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 79 years of age.
Phase: PHASE2 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 07:54 UTC
-
New injection after liver ablation aims to stop colorectal cancer in its tracks
Disease control Not yet recruitingThe goal of this clinical trial is to learn if a new injectable drug (IP-001), administered after standard liver tumor ablation, can help prevent cancer from returning in people (males/females, ≥18 years old) with colorectal cancer that has spread only to the liver. The study wil…
Phase: PHASE2, PHASE3 • Sponsor: Immunophotonics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New cream could ease painful skin condition lichen sclerosus
Disease control Recruiting nowThe main objective of the study is to evaluate the efficacy of twice daily applications of delgocitinib cream compared with cream vehicle in the treatment of adult participants with mild to severe lichen sclerosus (LS). The researchers are focusing on female participants because …
Phase: PHASE3 • Sponsor: LEO Pharma • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer.
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug targets brain tumors in lung cancer patients
Disease control Not yet recruitingA single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
Phase: PHASE2 • Sponsor: Maastricht University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail targets brain tumors from lung and breast cancer
Disease control TerminatedBrain metastasis represents one of the worst prognostic outcomes in advanced malignant tumors. Approximately 10% to 40% of patients with solid tumors develop brain metastases, a incidence rate significantly higher than that of primary malignant brain tumors. Over 80% of patients …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for rare kidney cancer: targeted drug plus radiation may replace chemo
Disease control Not yet recruitingThis randomized, open-label, multicenter phase II study is designed to compare disitamab vedotin plus radiotherapy with gemcitabine plus carboplatin as adjuvant treatment in patients with HER2-expressing upper tract urothelial carcinoma after radical nephroureterectomy (RNU). Eli…
Phase: PHASE2 • Sponsor: Peking University First Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Immunotherapy before surgery shows promise for oral cancer
Disease control Not yet recruitingThis is a Phase II, single-centre, non-randomized, single-arm clinical trial to investigate the efficacy and safety of neoadjuvant nivolumab therapy in adult participants with resectable, locoregionally advanced Oral Squamous Cell Carcinoma (OSCC) tumors. Identification of predic…
Phase: PHASE2 • Sponsor: Prof. Lars Olaf Cardell • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug duo aims to make inoperable sinus cancer removable
Disease control Recruiting nowThis prospective, multicenter clinical study aims to evaluate the efficacy and safety of neoadjuvant therapy with MRG003 (Becotatug vedotin) combined with epirubicin in patients with EGFR-positive, unresectable recurrent sinonasal adenoid cystic carcinoma (SNACC). The primary que…
Phase: PHASE2 • Sponsor: Eye & ENT Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New CAR-T therapy takes aim at tough lymphoma cancers
Disease control Not yet recruitingThis study is an open-label, single-arm, prospective clinical trial involving patients with relapsed/refractory B-cell lymphoma, aimed at evaluating the safety and efficacy of CAR-T cell infusion.
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Gene therapy hope for rare childhood disease AGU
Disease control Not yet recruitingThe goal of this clinical trial is to learn if the treatment is a safe, tolerable, and efficacious treatment for adults and children with Aspartylglucosaminuria (AGU).
Phase: PHASE1, PHASE2 • Sponsor: Rare Trait Hope • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug aims to cut opioid use after heart and Weight-Loss surgery
Symptom relief Recruiting nowThis is prospective, randomized study. The purpose of this study is to evaluate whether the addition of Suzetrigine to well established multimodal pain regimen for participants undergoing bariatric patients undergoing weight-loss surgery and cardiac patients undergoing sternotomy…
Phase: PHASE3 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Bone-Stretching trick may help heal diabetic foot wounds
Disease control Not yet recruitingThis study is a single-center, prospective, randomized controlled trial aimed at evaluating whether periosteal distraction combined with autologous split-thickness skin grafting can significantly improve graft survival rate at postoperative day 14 compared with skin grafting alon…
Phase: NA • Sponsor: Hu Zhicheng • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Brain cell injection offers new hope for advanced Parkinson's patients
Disease control Not yet recruitingThis clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of a single injection of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in patients with Parkinson's Disease who have previously undergone deep brain stimulation or deep brai…
Phase: PHASE1 • Sponsor: iRegene Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
Disease control Not yet recruitingThe purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Phase: PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo aims to turn untreatable lung tumors into surgical candidates
Disease control Not yet recruitingThe goal of this phase 2 trial is to evaluate the efficacy and safety of tislelizumab combined with intravenous chemotherapy and bronchial artery chemoembolization (BACE) as conversion therapy for patients with initially unresectable stage IIIA-IIIB non-small cell lung cancer (NS…
Phase: PHASE2 • Sponsor: Sichuan Cancer Hospital and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Arm cuff therapy may shield heart and brain after stroke
Disease control Not yet recruitingIntroduction: The management of acute myocardial injury following acute ischemic stroke (AMI-AIS), a frequent complication that severely worsens prognosis, is challenging. Remote ischemic conditioning (RIC) has demonstrated therapeutic potential in separate cardiac and cerebrovas…
Phase: PHASE3 • Sponsor: Capital Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Can a cancer drug wake up immune cells to beat HIV-Related infections?
Disease control Not yet recruitingThis prospective, single-arm, open-label study aims to evaluate the efficacy and safety of a PD-1 inhibitor (Sintilimab) combined with standard anti-infective therapy in patients with advanced HIV disease (AHD) who are suffering from refractory opportunistic infections (OIs). De…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Public Health Clinical Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New cell therapy targets hard-to-treat cancers with KRAS mutation
Disease control Not yet recruitingThis is a Phase 1/2, open-label, single-arm, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of DCTY1102 Injection in participants with advanced malignant tumors harboring KRAS/NRAS G12D mutations and positive for HLA-A11:01. DCT…
Phase: PHASE1 • Sponsor: Beijing DCTY Biotech Co.,Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can a heart drug shield kidneys during bypass surgery?
Prevention Not yet recruitingCardiac surgery-associated acute kidney injury (CSA-AKI) is a common and serious perioperative complication, independently associated with prolonged hospitalization, increased mortality, and progression to chronic kidney disease. Despite advances in surgical techniques and postop…
Phase: PHASE4 • Sponsor: China National Center for Cardiovascular Diseases • Aim: Prevention
Last updated Jun 27, 2026 13:00 UTC